Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties
Hristo L. Svilenov, Paolo Arosio, Tim Menzen, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 22

Showing 22 citing articles:

Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV
Aubin Ramon, Montader Ali, Misha Atkinson, et al.
Nature Machine Intelligence (2024) Vol. 6, Iss. 1, pp. 74-91
Open Access | Times Cited: 24
Blueprint for antibody biologics developability
Carl Mieczkowski, Xuejin Zhang, Dana Lee, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 28
Design and engineering of bispecific antibodies: insights and practical considerations
Andreas V. Madsen, Lasse Ebdrup Pedersen, Peter Kristensen, et al.
Frontiers in Bioengineering and Biotechnology (2024) Vol. 12
Open Access | Times Cited: 10
How can we discover developable antibody-based biotherapeutics?
Joschka Bauer, Nandhini Rajagopal, Priyanka Gupta, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 14
Comparison of the Protective Effect of Polysorbates, Poloxamer and Brij on Antibody Stability Against Different Interfaces
Dominik Zürcher, Severin Caduff, Laetitia Aurand, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 112, Iss. 11, pp. 2853-2862
Open Access | Times Cited: 9
AI/ML combined with next-generation sequencing of VHH immune repertoires enables the rapid identification of de novo humanized and sequence-optimized single domain antibodies: a prospective case study
Paul Arras, Han Byul Yoo, Lukas Pekar, et al.
Frontiers in Molecular Biosciences (2023) Vol. 10
Open Access | Times Cited: 8
Facilitating high throughput bispecific antibody production and potential applications within biopharmaceutical discovery workflows
Caitlin Fawcett, Joseph Tickle, C.H. Coles
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 2
A comparative study of the developability of full-length antibodies, fragments, and bispecific formats reveals higher stability risks for engineered constructs
Itzel Condado Morales, Fabian Dingfelder, Isabel Waibel, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 2
Impact of Deep Eutectic Solvents on Kinetics and Folding Stability of Formate Dehydrogenase
Nicolás F. Gajardo‐Parra, Gabriel Rodríguez-Romo, Andrés F. Arroyo-Avirama, et al.
Processes (2023) Vol. 11, Iss. 10, pp. 2815-2815
Open Access | Times Cited: 7
Real‐Time Observation of Protein Aggregation at Liquid‐Liquid Interfaces in a Microfluidic Device
Dominik Zürcher, Klaus Wuchner, Paolo Arosio
Small (2024) Vol. 20, Iss. 45
Open Access | Times Cited: 1
AbNatiV: VQ-VAE-based assessment of antibody and nanobody nativeness for hit selection, humanisation, and engineering
Aubin Ramon, Montader Ali, Misha Atkinson, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Exploring a Role for Flow-Induced Aggregation Assays in Platform Formulation Optimisation for Antibody-Based Proteins
Leon F. Willis, Vishal M. Toprani, Sashini Wijetunge, et al.
Journal of Pharmaceutical Sciences (2023) Vol. 113, Iss. 3, pp. 625-636
Open Access | Times Cited: 3
Modelling bi-specific antibodies in aqueous solution
Taras Hvozd, Yu. V. Kalyuzhnyi, Vojko Vlachy
Journal of Molecular Liquids (2024) Vol. 402, pp. 124740-124740
Open Access
Molecular properties and diagnostic potential of monoclonal antibodies targeting cytotoxic α-synuclein oligomers
Janni Nielsen, Johanne Lauritsen, Jannik Nedergaard Pedersen, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access
Bispecific FpFs: a versatile tool for preclinical antibody development
Matthew Collins, Nkiruka Ibeanu, Wiktoria Roksana Grabowska, et al.
RSC Chemical Biology (2024)
Open Access
Predictive Model Building for Aggregation Kinetics Based on Molecular Dynamics Simulations of an Antibody Fragment
Yuhan Wang, Hywel D. Williams, Duygu Dikicioǧlu, et al.
Molecular Pharmaceutics (2024)
Open Access
Rationalizing mAb Candidate Screening Using a Single Holistic Developability Parameter
Leon F. Willis, Isabelle Trayton, Janet C. Saunders, et al.
Molecular Pharmaceutics (2024) Vol. 22, Iss. 1, pp. 181-195
Open Access
Biophysical Analysis of Therapeutic Antibodies in the Early Development Pipeline
Leon F. Willis, Nikil Kapur, Sheena E. Radford, et al.
Biologics (2024) Vol. Volume 18, pp. 413-432
Open Access
De Novo Antibody Design with SE(3) Diffusion
Daniel Cutting, Frédéric A. Dreyer, David Errington, et al.
Journal of Computational Biology (2024)
Closed Access
Matrixed CDR-grafting: a neoclassical framework for antibody humanization and developability
Pankaj Gupta, Alexander M. Horspool, Goral Trivedi, et al.
Journal of Biological Chemistry (2023) Vol. 300, Iss. 1, pp. 105555-105555
Open Access
Monoclonal antibodies targeting cytotoxic α-synuclein oligomers: molecular properties and diagnostic potential
Daniel E. Otzen, Janni Nielsen, Johanne Lauritsen, et al.
Research Square (Research Square) (2023)
Open Access
Page 1

Scroll to top